We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 159

Canadian patent law: 2014 year in review

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 18 2015

This article summarises noteworthy Canadian patent law decisions and developments from 2014. Court of Appeal addresses patent utility in Celebrex The

Re-examination: a viable alternative in Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • March 13 2015

The Federal Court of Appeal recently upheld the dismissal of an appeal from a decision of a Patent Re-examination Board thus establishing that

Canadian patent law: 2014 year in review

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 26 2015

Canadian Courts have continued to address allegations that patents are invalid because they lack utility. A notable 2014 Court of Appeal decision in

Revue de l'année 2014 en matière de brevets

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 26 2015

Les tribunaux canadiens ont continué de se pencher sur des allégations selon lesquelles certains brevets sont invalides pour motif d’absence

Federal Court rejects NIA defence and awards compound interest on patent damages

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 24 2015

On Jan. 23, 2015, the Federal Court released its decision regarding the quantum of damages recoverable by Eli Lilly (“Lilly”) in an action relating

Federal Court determines Minister's decisions granting NOCS based on administrative ANDSs cross-referencing licensed generics without requiring NOAs are wrong

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 10 2015

On December 19, 2014, the Federal Court set aside a decision of the Minister of Health granting a Notice of Compliance (NOC) to Teva authorizing the

Listing patents against combination drugs in Canada ? Changes coming

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • December 1 2014

On Nov. 26, 2014, Industry Canada announced an important proposed change to the eligibility requirements for listing a patent against a drug in

Court of Appeal again interprets utility requirement in Celebrex FCA

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 1 2014

The Federal Court of Appeal has again discussed the so-called “promise doctrine” in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc

Application for leave to appeal granted - 30 October 2014

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 30 2014

On appeal from the judgment of the Federal Court of Appeal pronounced March 14, 2014. The applicants (collectively, “Sanofi”) are the pat

Dow v NOVA: case summary

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • September 19 2014

In the Federal Court's decision in The Dow Chemical Company et al v NOVA Chemicals Corporation, 2014 FC 844 ("Dow v NOVA"), in the face of a